糖适平治疗271例NIDDM的临床评价  

A CLINICAL EVALUATION OF GLURENORM IN THE TREATMENT OF TYPE Ⅱ DIABETES MELLITUS

作　　者：李秀钧[1] 金星[2] 李美莲[3] 于国宁[4] 刘颖耿 刘永志[6] 张喆[7] 许樟荣 刘雪萍 冯登尧 冯颖[11] 邓尚平[1] J.Limmer 池芝盛[13] 

机构地区：[1]华西医科大学,610041 [2]北京铁路总医院 [3]北京酒仙桥医院 [4]天津第一中心医院 [5]山西忻州地区医院 [6]衡阳医学院 [7]天津市公安医院 [8]解放军514医院 [9]本溪钢铁公司职工总医院 [10]四川仁寿人民医院 [11]鞍山钢铁公司铁西医院 [12]Boehringer Ingelheim/Thomae临床部 [13]北京协和医院

出　　处：《中华内分泌代谢杂志》1993年第1期8-11,共4页Chinese Journal of Endocrinology and Metabolism

摘　　要：271例Ⅱ型糖尿病患者经用糖适平(GL)治疗5或7个月后,空腹及餐后血糖、HbA_1、尿糖及尿蛋白均较治疗前明显降低(P<0.01).空腹及餐后血糖分别较治前平均降低21.48％和25.41％。GL治疗总有效率为85.6％。低血糖反应发生率为0.7％。其他副反应有嗜睡6例,瘙痒、腹胀和面部刺痛各1例。血像及肝肾功能无特殊变化。本药适应证除与一般磺脲类(SU)相同外,尤适于:(1)老年糖尿病;(2)糖尿病伴轻至中度肾功能减退;(3)用其他SU反复有低血糖发作者;(4)其他SU失效者。GL剂量为112.40±66.50mg/d(15～270mg/d),较国外报告为高。271 cases of NIDDM treated for 5 or 7 months with Glurenorm (GL) were studied. After 5-month treatment with GL the FBG and PBG decreased significantly from 9.87±0.18 to 7.78±0.11 mmol/L (P<0.01), and from 15.27±0.30 to 11.39±0.21 mmol/L (P<0.01), respectively. So did the HbA1,UG and UP. A 5-month treatment of GL yielded an effective glucose-lowering rate of 85.6% with an average daily dose of 112.4±66.5 mg (15-270 mg). The occurrence of hypoglycemic events (mild) was 0.7%. No other serious side effects were found. Thus, GL is a safe and effective sulfonylurea (SU) with very low risk of hypoglycemia. It can be indicated for all NIDDM patients suitable for other SU, and especially appropriate for: 1) elderly diabetics; 2) diabetic nephropalhy with mild to moderate renal insufficiency; 3) recurrent and severe episodes of hypoglycemia after treatment with other SU.

关 键 词：糖适平 糖尿病 降血糖药 药物疗法 

分 类 号：R587.105[医药卫生—内分泌]